Skip to main content

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Publication ,  Journal Article
Hsi, ED; Li, H; Nixon, AB; Schöder, H; Bartlett, NL; LeBlanc, M; Smith, S; Kahl, BS; Leonard, JP; Evens, AM; Scott, DW; Rimsza, LM; Friedberg, JW
Published in: Blood
April 18, 2019

Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)-positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

April 18, 2019

Volume

133

Issue

16

Start / End Page

1762 / 1765

Location

United States

Related Subject Headings

  • Therapeutics
  • Survival Analysis
  • Receptors, Cell Surface
  • Prognosis
  • Positron-Emission Tomography
  • Middle Aged
  • Male
  • Interleukin-10
  • Immunology
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hsi, E. D., Li, H., Nixon, A. B., Schöder, H., Bartlett, N. L., LeBlanc, M., … Friedberg, J. W. (2019). Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood, 133(16), 1762–1765. https://doi.org/10.1182/blood-2018-08-870915
Hsi, Eric D., Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, et al. “Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.Blood 133, no. 16 (April 18, 2019): 1762–65. https://doi.org/10.1182/blood-2018-08-870915.
Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019 Apr 18;133(16):1762–5.
Hsi, Eric D., et al. “Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.Blood, vol. 133, no. 16, Apr. 2019, pp. 1762–65. Pubmed, doi:10.1182/blood-2018-08-870915.
Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019 Apr 18;133(16):1762–1765.

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

April 18, 2019

Volume

133

Issue

16

Start / End Page

1762 / 1765

Location

United States

Related Subject Headings

  • Therapeutics
  • Survival Analysis
  • Receptors, Cell Surface
  • Prognosis
  • Positron-Emission Tomography
  • Middle Aged
  • Male
  • Interleukin-10
  • Immunology
  • Humans